Alar Pharmaceuticals Inc.
4Patents
4Active
4Granted
43Portfolio score
Filing activity: Sep 12, 2017 → Jan 10, 2020
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11524965B2 | Long-acting injectable formulations and crystalline forms of buprenorphine derivatives | Chemistry; Metallurgy | 0 | Active |
| US10744132B2 | Sustained-release buprenorphine formulations | Human Necessities | 0 | Active |
| US11981617B2 | Ketamine pamoate and use thereof | Chemistry; Metallurgy | 0 | Active |
| US12201630B2 | Naltrexone injectable sustained release formulation | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.